

FOLEY & LARDNER

ATTORNEYS AT LAW

11250 EL CAMINO REAL, SUITE 200
SAN DIEGO, CA 92130
P.O. BOX 80278
SAN DIEGO, CALIFORNIA 92138-0278
TELEPHONE: 858.847.6700
FACSIMILE: 858.792.6773
WWW.FOLEYLARDNER.COM

FACSIMILE TRANSMISSION**Total # of Pages: 18 (including this page)**

TO:	PHONE #:	FAX #:
Examiner Robert M. DeWitty, Art Unit 1616 U.S. Patent and Trademark Office	(703) 308-2411	(703) 872-9307 308-7924

From : Stephen E. Reiter
Sender's Direct Dial : 858.847.6711 *SE*
Date : August 26, 2002
Client/Matter No : 071243-1317
User ID No : 1877

MESSAGE:**OFFICIAL**

Re: Application Serial No. 09/847,945

Please Enter

Following are:

Amendment Transmittal (2 pgs.-in dupl.);
Petition for Extension of Time (1 pg.);
Change of Correspondence Address (1 pg.);
Response (3 pgs. + 2 pg. enclosure);
Information Disclosure Statement (2 pgs.);
Form PTO-1449 (4 pgs.).

If there are any problems with this transmission or if you have not
received all of the pages, please call 858.847.6700.


Operator:	Time Sent:	Return Original To: Joy Day
-----------	------------	--------------------------------

CONFIDENTIALITY NOTICE: THE INFORMATION CONTAINED IN THIS FACSIMILE MESSAGE IS INTENDED ONLY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE DESIGNATED RECIPIENTS NAMED ABOVE. THIS MESSAGE MAY BE AN ATTORNEY-CLIENT COMMUNICATION, AND AS SUCH IS PRIVILEGED AND CONFIDENTIAL. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR ANY AGENT RESPONSIBLE FOR DELIVERING IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS DOCUMENT IN ERROR, AND THAT ANY REVIEW, DISSEMINATION, DISTRIBUTION OR COPYING OF THIS MESSAGE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.

Atty. Dkt. No. ABI1460-3
(071243-1317)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Desai et al.
Title: COMPOSITIONS AND METHODS
FOR TREATMENT OF
HYPERPLASIA
Appl. No.: 09/847,945
Filing Date: 05/02/2001
Examiner: R. DeWitty
Art Unit: 1616

CERTIFICATE OF FACSIMILE TRANSMISSION	
I hereby certify that this paper is being facsimile transmitted to the United States Patent and Trademark Office, Washington, D.C. on the date below.	
<u>Stephen E. Reiter</u>	
(Printed Name)	
<u></u>	
(Signature)	
<u>August 26, 2002</u>	
(Date of Deposit)	

AMENDMENT TRANSMITTAL

Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith is a Response in the above-identified application.

- [] Small Entity status under 37 C.F.R. § 1.9 and § 1.27 has been established by a Small Entity statement previously submitted.
- [X] Information Disclosure Statement is enclosed.
- [X] Change of Correspondence Address is enclosed.
- [X] The fee required for additional claims is calculated below:

	Claims as Amended	Previously Paid For	Extra Claims Present	Rate	Additional Claims Fee
Total Claims:	30	30	0	x \$18.00	\$0.00
Independents:	7	7	0	x \$84.00	\$0.00
First presentation of any Multiple Dependent Claims:				+ \$280.00	\$0.00
CLAIMS FEE TOTAL:					\$0.00

- [X] Applicant hereby petitions for an extension of time under 37 C.F.R. § 1.136(a) for the total number of months checked below:

Atty. Dkt. No. ABI1460-3
(071243-1317)

<input type="checkbox"/>	Extension for response filed within the first month:	\$110.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the second month:	\$400.00	\$0.00
<input checked="" type="checkbox"/>	Extension for response filed within the third month:	\$920.00	\$920.00
<input type="checkbox"/>	Extension for response filed within the fourth month:	\$1,440.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the fifth month:	\$1,960.00	\$0.00
	SUBTOTAL		\$920.00
	FEE FOR INFORMATION DISCLOSURE STATEMENT:		\$180.00
<input type="checkbox"/>	Small Entity Fees Apply (subtract ½ of above):		\$0.00
	TOTAL FEE:		\$1100.00

- ☒ Please charge Deposit Account No. 50-0872 in the amount of \$1100.00. A duplicate copy of this transmittal is enclosed.
- ☐ A check in the amount of \$_____ is enclosed.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date: August 26, 2002

By



FOLEY & LARDNER
P.O. Box 80278
San Diego, California 92138-0278
Telephone: (858) 847-6711
Facsimile: (858) 792-6773

Stephen E. Reiter
Attorney for Applicant
Registration No. 31,192

RECEIVED

JAN 29 2002

**UNITED STATES PATENT AND TRADEMARK OFFICE**

U.S. DEPT.
FOLEY & LARDNER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/847,945	05/02/2001	1614	1386	ABI1460-3 (071243-1317)	2	30	7

CONFIRMATION NO. 6174

UPDATED FILING RECEIPT



"OC000000007340986"

Stephen E. Reiter
 FOLEY & LARDNER
 23rd Floor
 402 West Broadway
 San Diego, CA 92101-3542

Date Mailed: 01/22/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Neil P. Desai, Los Angeles, CA;
 Patrick Soon-Shiong, Los Angeles, CA;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CIP OF 09/446,783 05/16/2000
 WHICH CLAIMS BENEFIT OF 60/051,021 06/27/1997

Foreign Applications

PCT/US98/13272 06/26/1998

If Required, Foreign Filing License Granted 06/29/2001

Projected Publication Date: Request for Non-Publication Acknowledged

Non-Publication Request: Yes

*****WARNING*****

Applicant has requested non-publication, certifying that the invention disclosed in this application has not been and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing; and has also claimed the benefit of an application filed in another country or under a multilateral agreement. Because the non-publication request and corresponding certification appears to be inconsistent with the priority claim, applicant is reminded that he/she has an

DOCKETED

JAN 29 2002

obligation to promptly notify the Office and rescind the non-publication request if the invention disclosed in this application is the subject of an application filed in another country, or under a multilateral agreement, that requires eighteen-month publication.

*****WARNING*****

Early Publication Request: No

Title

Compositions and methods for treatment of hyperplasia

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).